MedTrace Logo

VA106483 and Alpha Blocker Interaction Study in Elderly Males

NCT00879216 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2009-11-25

No results posted yet for this study

Summary

The main purpose of this study is to investigate whether the hypotensive effects of an alpha-blocker are increased when VA106483 is given at the same time.

Conditions

  • Nocturia

Interventions

DRUG

VA106483

4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.

DRUG

Placebo

4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.

Sponsors & Collaborators

  • Vantia Ltd

    lead INDUSTRY

Principal Investigators

  • Medical Director · Charles River Clinical Services, Edinburgh, UK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-05-31
Completion
2009-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00879216 on ClinicalTrials.gov